iTeos Therapeutics, Inc. (NASDAQ:ITOS) Holdings Trimmed by …

3 days ago · Franklin Resources Inc. cut its holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS – Free Report) by 68.9% during the 3rd quarter, according to the company in its most recent disclosure with the ...

CouponFollow Extension

9%
OFF

ITeos Therapeutics, Inc. (NASDAQ:ITOS) Holdings Trimmed By …

3 weeks from now

defenseworld.net

4%
OFF

ITeos Therapeutics (ITOS) News Today - MarketBeat

3 weeks from now

3 days ago · Vestal Point Capital LP trimmed its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 41.4% during the third quarter, according to its most recent disclosure with …

marketbeat.com

4%
OFF

Barclays PLC Sells 9,064 Shares Of ITeos Therapeutics, Inc.

3 weeks from now

Dec 30, 2024 · Barclays PLC trimmed its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS – Free Report) by 7.4% during the 3rd quarter, according to its most recent …

americanbankingnews.com

$7.32
OFF

ITeos Therapeutics, Inc. (NASDAQ:ITOS) Stock Holdings Lessened …

3 weeks from now

Dec 30, 2024 · ITOS stock opened at $7.32 on Monday. The firm has a 50 day simple moving average of $8.33 and a 200 day simple moving average of $12.26. iTeos Therapeutics, Inc. …

defenseworld.net

$18.75
OFF

Iteos Therapeutics Inc Stock - WallStreetZen

3 weeks from now

Dec 6, 2024 · Allspring Global Investments Holdings LLC Trims Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) ... (NASDAQ: ITOS) Iteos Therapeutics's 52-week high was $18.75, and …

wallstreetzen.com

9%
OFF

State Street Corp Increases Position In ITeos Therapeutics, Inc ...

3 weeks from now

Dec 26, 2024 · State Street Corp grew its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 21.9% in the third quarter, according to the company in its …

marketbeat.com

7%
OFF

Quest Partners LLC Has $113,000 Holdings In ITeos Therapeutics, …

3 weeks from now

Nov 30, 2024 · Quest Partners LLC lifted its holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS – Free Report) by 914.7% during the third quarter, according to its most recent Form 13F filing …

defenseworld.net

9%
OFF

Charles Schwab Investment Management Inc. Buys 8,397 Shares Of …

3 weeks from now

Dec 16, 2024 · Charles Schwab Investment Management Inc. raised its holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS – Free Report) by 3.9% in the third quarter, …

etfdailynews.com

$25.50
OFF

ITOS - ITeos Therapeutics, Inc. (NasdaqGM) - Share Price And …

3 weeks from now

The average one-year price target for iTeos Therapeutics, Inc. is $25.50. The forecasts range from a low of $16.16 to a high of $49.35. A stock’s price target is the price at which analysts …

fintel.io

$7.47
OFF

State Street Corp Increases Holdings In ITeos Therapeutics, Inc ...

3 weeks from now

Dec 26, 2024 · Shares of NASDAQ:ITOS opened at $7.47 on Thursday. iTeos Therapeutics, Inc. has a 12 month low of $7.09 and a 12 month high of $18.75. The stock has a market cap of …

defenseworld.net

$1.05
OFF

ITeos Therapeutics (ITOS) Earnings Date And Reports 2025

3 weeks from now

3 days ago · iTeos Therapeutics issued Q3 2024 earnings on November 12, 2024, reporting an EPS of -$1.05, which beat the consensus estimate of -$1.18 by $0.13. With a trailing EPS of …

marketbeat.com

$86621
OFF

Kreg Therapeutics, Inc. Careers In North Bergen, NJ

3 weeks from now

Kreg Therapeutics, Inc. salaries in North Bergen, NJ. Salary estimated from 23 employees, users, and past and present job advertisements on Indeed. Clinic Manager. $86,621 per year. …

indeed.com

1%
OFF

Jane Street Group LLC Lowers Stock Holdings In Voyager …

3 weeks from now

23 hours ago · Jane Street Group LLC trimmed its holdings in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 56.1% in the 3rd quarter, according to its most recent …

marketbeat.com

$36000
OFF

Veeco Holdings Careers In North Bergen, NJ | Indeed.com

3 weeks from now

Jun 8, 2015 · Veeco Holdings salaries in North Bergen, NJ. Salary estimated from 1 employees, users, and past and present job advertisements on Indeed. Warehouse Worker. $36,000 per …

indeed.com

3%
OFF

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Holdings Trimmed

3 weeks from now

4 days ago · JPMorgan Chase & Co. cut its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 13.3% during the 3rd quarter, according to the company in …

marketbeat.com

FAQs about iTeos Therapeutics, Inc. (NASDAQ:ITOS) Holdings Trimmed by … Coupon?

How much is iTeos Therapeutics stock now?

iTeos Therapeutics' stock was trading at $10.95 at the start of the year. Since then, ITOS stock has decreased by 33.2% and is now trading at $7.32. How were iTeos Therapeutics' earnings last quarter? iTeos Therapeutics, Inc. (NASDAQ:ITOS) issued its quarterly earnings results on Tuesday, November, 12th. ...

How much does iTeos Therapeutics (ITOS) earn?

iTeos Therapeutics (NASDAQ:ITOS) has a recorded net income of $96.65 million. ITOS has generated -$0.80 earnings per share over the last four quarters. What is iTeos Therapeutics's EPS forecast for next year? ...

Does iTeos Therapeutics (ITOs) have a free account?

Register for your free account today at data.nasdaq.com. Discover real-time iTeos Therapeutics, Inc. Common Stock (ITOS) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq. ...

Who is iTeos Therapeutics?

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. ...

What does iTeos stand for?

WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 05, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and d... iTeos Therapeutics is developing an anti-TIGIT molecule for various cancers, partnering with GSK and advancing to late-stage clinical studies. ...

Will iTeos belrestotug help fight lung cancer?

U.S. stock futures were mixed this morning, with the Dow futures gaining around 100 points on Monday. iTeos Therapeutics' belrestotug shows promising response rates in lung cancer trials, especially when combined with dostarlimab, despite significant safety concerns. Financially, ITOS has over 3 years... ...